79 related articles for article (PubMed ID: 32621051)
1. Molecular characterisation and clinical correlation of papillary thyroid microcarcinoma.
Samà MT; Grosso E; Mele C; Laurora S; Monzeglio O; Marzullo P; Boldorini R; Aluffi Valletti P; Aimaretti G; Scatolini M; Pagano L
Endocrine; 2021 Jan; 71(1):149-157. PubMed ID: 32621051
[TBL] [Abstract][Full Text] [Related]
2. Whether Detection of Gene Mutations Could Identify Low- or High-Risk Papillary Thyroid Microcarcinoma? Data from 393 Cases Using the Next-Generation Sequencing.
Jin L; Zhou L; Wang JB; Tao L; Lu XX; Yan N; Chen QM; Cao LP; Xie L
Int J Endocrinol; 2024; 2024():2470721. PubMed ID: 38268989
[TBL] [Abstract][Full Text] [Related]
3. Effect of Pregnancy and Menopause on Micropapillary Thyroid Carcinomas During Active Surveillance.
Ghirri A; Campopiano MC; Prete A; Matrone A; Gambale C; Piaggi P; Rago T; Scutari M; Elisei R; Molinaro E
J Endocr Soc; 2023 Aug; 7(9):bvad109. PubMed ID: 37873501
[TBL] [Abstract][Full Text] [Related]
4. Papillary thyroid microcarcinoma: not always indolent.
Ena J; Gómez-Tierno A
Rev Clin Esp; 2021 Mar; 221(3):157-159. PubMed ID: 32416927
[No Abstract] [Full Text] [Related]
5. Association between BRAF
Sezer H; Uren N; Yazici D
North Clin Istanb; 2020; 7(4):321-328. PubMed ID: 33043255
[TBL] [Abstract][Full Text] [Related]
6. Presence of TERT ± BRAF V600E mutation is not a risk factor for the clinical management of patients with papillary thyroid microcarcinoma.
Lee J; Ha EJ; Roh J; Kim HK
Surgery; 2021 Sep; 170(3):743-747. PubMed ID: 33952391
[TBL] [Abstract][Full Text] [Related]
7. Indications and Strategy for Active Surveillance of Adult Low-Risk Papillary Thyroid Microcarcinoma: Consensus Statements from the Japan Association of Endocrine Surgery Task Force on Management for Papillary Thyroid Microcarcinoma.
Sugitani I; Ito Y; Takeuchi D; Nakayama H; Masaki C; Shindo H; Teshima M; Horiguchi K; Yoshida Y; Kanai T; Hirokawa M; Hames KY; Tabei I; Miyauchi A
Thyroid; 2021 Feb; 31(2):183-192. PubMed ID: 33023426
[No Abstract] [Full Text] [Related]
8. The predictive value of coexisting BRAFV600E and TERT promoter mutations on poor outcomes and high tumour aggressiveness in papillary thyroid carcinoma: A systematic review and meta-analysis.
Chen B; Shi Y; Xu Y; Zhang J
Clin Endocrinol (Oxf); 2021 May; 94(5):731-742. PubMed ID: 32816325
[TBL] [Abstract][Full Text] [Related]
9. [Predictors for central lymph node metastases in papillary thyroid microcarcinoma].
Wu Y; Wang J; Liu Q
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2020 Oct; 34(10):955-957. PubMed ID: 33254308
[No Abstract] [Full Text] [Related]
10. Prevalence of
Rashid FA; Munkhdelger J; Fukuoka J; Bychkov A
Gland Surg; 2020 Oct; 9(5):1878-1900. PubMed ID: 33224863
[TBL] [Abstract][Full Text] [Related]
11. Management of Lateral Multiple-Level Metastasis in N1b Papillary Thyroid Microcarcinoma.
Wang W; Zhang Z; Zhao Y; Xue W; Xia F; Li X
Front Oncol; 2020; 10():1586. PubMed ID: 32984020
[No Abstract] [Full Text] [Related]
12. Clinical and molecular features of progressive papillary thyroid microcarcinoma.
Wang Z; Ji X; Zhang H; Sun W
Int J Surg; 2024 Apr; 110(4):2313-2322. PubMed ID: 38241301
[TBL] [Abstract][Full Text] [Related]
13. A nomogram based on ultrasound radiomics for predicting the invasiveness of cN0 single papillary thyroid microcarcinoma.
Zhang M; Lyu S; Yang L; Wei H; Liu R; Wang X; Liu Y; Zhang B; Kwok JKS; Zhang Y
Gland Surg; 2023 Dec; 12(12):1735-1745. PubMed ID: 38229850
[TBL] [Abstract][Full Text] [Related]
14. Mortality rate and causes of death in papillary thyroid microcarcinoma.
Heo J; Ryu HJ; Park H; Kim TH; Kim SW; Oh YL; Chung JH
Endocrine; 2024 Mar; 83(3):671-680. PubMed ID: 37814113
[TBL] [Abstract][Full Text] [Related]
15. Risk factors associated with lymph node metastasis in patients with small papillary thyroid carcinomas.
Sun H; Liu M
Int J Clin Exp Pathol; 2023; 16(5):86-93. PubMed ID: 37293137
[TBL] [Abstract][Full Text] [Related]
16. Multi-omics profiling of papillary thyroid microcarcinoma reveals different somatic mutations and a unique transcriptomic signature.
Li Q; Feng T; Zhu T; Zhang W; Qian Y; Zhang H; Zheng X; Li D; Yun X; Zhao J; Li Y; Yu H; Gao M; Qian B
J Transl Med; 2023 Mar; 21(1):206. PubMed ID: 36941725
[TBL] [Abstract][Full Text] [Related]
17. Combined expression of the
Zhang M; Gu J; Wang W; Wang K; Zheng L; Feng J; Shang J
Gland Surg; 2022 Dec; 11(12):1908-1923. PubMed ID: 36654945
[TBL] [Abstract][Full Text] [Related]
18.
Parvathareddy SK; Siraj AK; Iqbal K; Qadri Z; Ahmed SO; Al-Rasheed M; AlQatie AA; Al-Sobhi SS; Al-Dayel F; Al-Kuraya KS
Front Endocrinol (Lausanne); 2022; 13():808298. PubMed ID: 35360077
[TBL] [Abstract][Full Text] [Related]
19. Different Threshold of Malignancy for
Kakudo K
Cancers (Basel); 2022 Feb; 14(3):. PubMed ID: 35159081
[TBL] [Abstract][Full Text] [Related]
20. BRAF
Chen H; Song A; Wang Y; He Y; Tong J; Di J; Li C; Zhou Z; Cai X; Zhong D; Da J
Cancer Med; 2022 Jan; 11(1):40-49. PubMed ID: 34851044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
